美股市场个股详情
KZIA Kazia Therapeutics
- 0.280
- +0.005+1.67%
交易中 05/21 11:45 (美东)
737.07万总市值-751市盈率TTM
0.286最高价0.236最低价3.11万股成交量0.275今开0.275昨收8252.59成交额0.13%换手率亏损市盈率(静)2636.15万总股本1.34052周最高2.10市净率663.28万流通值0.18752周最低--股息TTM2372.23万流通股15.850历史最高--股息率TTM18.15%振幅0.187历史最低0.265平均价1股每手
Kazia Therapeutics股票讨论区
登录发表评论
$Kazia Therapeutics(KZIA.US$ SYDNEY, May 1, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce that the Safety Review Team (SRT) of the EVT801 Phase 1 clinical trial has concluded that the primary and secondary objectives of stage 1 of the trial have successfully been met. It shoulda been a weight loss drug making good advancement! It would be climbing then! Hehehe![]()
3
9
$Kazia Therapeutics(KZIA.US$ Kazia Therapeutics Ltd - Pursuant to Purchase Agreement, May Sell to Alumni Capital up to $15 Mln of American Depositary Shares From Time to Time
1
Taking a look at $Kazia Therapeutics(KZIA.US$
Here's a look at the current concensus:
Reasons to consider adding this to your portfolio:
What is the Fibonacci indicating?
Short Interest:
Remember to pay attention to the Moving Average (MA) and Volume-weighted average price (VWAP) before hoping on board!
Good Luck and Happy Trading!
Here's a look at the current concensus:
Reasons to consider adding this to your portfolio:
What is the Fibonacci indicating?
Short Interest:
Remember to pay attention to the Moving Average (MA) and Volume-weighted average price (VWAP) before hoping on board!
Good Luck and Happy Trading!
+8
$Kazia Therapeutics(KZIA.US$ Kazia Therapeutics Licenses Paxalisib To Sovargen For Intractable Seizures In Rare Central Nervous System Diseases
1
3
$Annovis Bio(ANVS.US$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$迪卡斯(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$迪卡斯(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
10
1
In the world of biotechnology, every new development is a potential game changer, and the recent announcement by Kazia Therapeutics Limited ($KZIA) certainly fits the bill. The company has reported an early conclusion of their clinical trial after successfully reaching the primary endpoint. But what does this mean for you, the reader? Let's delve into it.
https://stockregion.app/p/therapeutics-company-reports-early
https://stockregion.app/p/therapeutics-company-reports-early
1
$Kazia Therapeutics(KZIA.US$ 利好都扶不起来 真是浪费我的时间
1
1
$Kazia Therapeutics(KZIA.US$ Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
3 MINUTES AGO, 7:30 AM EST
VIA PR NEWSWIRE
3 MINUTES AGO, 7:30 AM EST
VIA PR NEWSWIRE
3
2
Kazia's CEO, Dr. John Friend, expressed delight at the appointments, stating that Apple's deep biopharmaceutical leadership experience across finance, business development, and commercial operations will be extremely valuable for the company as it enters its next phase of growth.
暂无评论
分析
目标价预测
暂无数据
热议
美股
综合热度
股票代码
最新价
涨跌幅
Jaguar8 : It might climb later since it’s overweight issue
Stock_Drift : I’m in.
thanks
Trytosaveabit楼主 Stock_Drift: You’re welcome GL
Mod Tan : they just issue the prospectus, diluting shares again.
Trytosaveabit楼主 Mod Tan: It’s a amendment to the one filed back in February! May not have much of a affect? Need to finish updated price/amount! GL
查看更多评论...